Mood stabilizers are a specialized group of medications prescribed primarily to manage conditions like bipolar disorder, which involve extreme shifts in energy, mood, and activity levels. In Nigerian midwifery practice, recognizing the signs of severe mood instability is vital because pregnancy and the postpartum period can trigger or worsen psychiatric episodes. These medications help smooth out dangerous highs, such as mania, and devastating lows, like severe depression. When a pregnant woman takes a mood stabilizer, it crosses the placenta, meaning midwives must balance maternal mental stability against potential risks to the developing fetus. Collaborative care involving psychiatrists, obstetricians, and midwives ensures that mothers remain stable without exposing the baby to unnecessary harm. Stabilizing a mother's mood protects her ability to bond with her infant, reduces the risk of self-harm, and supports a healthier family environment.
Understanding how mood stabilizers work helps midwives anticipate both therapeutic effects and adverse reactions. The category includes traditional salts as well as certain anticonvulsants repurposed for psychiatric care.
Mood stabilizers are indicated when a woman has a documented history of bipolar I or II disorder, schizoaffective disorder, or severe treatment-resistant depression. During pregnancy, unmanaged bipolar disorder carries a high risk of relapse, which can lead to exhaustion, dangerous impulsive behaviors, and poor antenatal attendance. Postpartum psychosis, a psychiatric emergency often linked to underlying bipolar illness, poses a severe threat to both mother and newborn if prophylaxis is not maintained. Midwives encounter women who may have discontinued their medications out of fear, leading to rapid symptom return. Evaluating the severity of the psychiatric history helps the healthcare team determine if continuing mood stabilizers is safer than stopping them. Preventing a relapse is often the primary goal, as maternal emotional collapse severely disrupts infant caregiving and attachment.
Exposure to mood stabilizers during the first trimester carries distinct teratogenic risks that require careful counselling. Midwives should be familiar with the specific structural anomalies linked to these drugs so they can support informed patient decisions.
| Medication | Primary Fetal Risk | Critical Window |
|---|---|---|
| Lithium | Ebstein's anomaly (rare cardiac valve defect) | First trimester |
| Valproic Acid | Neural tube defects (spina bifida), cognitive delay | First trimester |
| Carbamazepine | Neural tube defects, craniofacial abnormalities | First trimester |
| Lamotrigine | Lower overall teratogenic risk compared to valproate | First trimester |
Despite these risks, uninformed discontinuation can lead to maternal relapse, which indirectly harms the fetus through poor nutrition, substance use, or self-harm. Therefore, risk-benefit analyses must be individualized rather than relying on blanket bans.
Managing mood stabilizers across pregnancy requires physiological adjustments, particularly because renal clearance increases as pregnancy progresses. For drugs like lithium, maternal blood volume expansion and increased glomerular filtration rates can cause serum levels to drop dangerously low, threatening relapse. Midwives must understand the need for frequent therapeutic drug monitoring throughout gestation. As the birth approaches, clinicians often adjust doses or temporarily withhold certain drugs, such as lithium, right before delivery to prevent neonatal toxicity. In the immediate postpartum period, renal function normalizes rapidly, which can cause serum lithium levels to spike sharply if doses are not reduced back to pre-pregnancy levels. Close supervision during the transition home prevents postpartum psychiatric crises while protecting the mother from drug toxicity.
Deciding whether to breastfeed while taking mood stabilizers involves weighing the protective benefits of human milk against infant drug exposure. Most psychiatric medications pass into breast milk to varying degrees, with lithium and carbamazepine transferring in significant amounts, whereas lamotrigine transfers moderately. When a mother chooses to breastfeed while on lithium, the neonate requires regular serum level checks, alongside monitoring for lethargy, poor muscle tone, poor feeding, and blue-gray skin discoloration. Midwives teach mothers to watch for signs of infant dehydration, such as dry mucous membranes or fewer wet diapers, because any fluid loss in the baby can drastically concentrate lithium levels in their blood. Open communication allows the healthcare team to support safe lactation while keeping a vigilant eye on the newborn's well-being.
Midwives play a frontline role in monitoring women prescribed mood stabilizers by conducting thorough routine assessments during antenatal and postnatal visits. Surveillance includes watching for early signs of drug toxicity, such as persistent tremor, severe nausea, vomiting, dizziness, blurred vision, and confusion. Midwives must educate patients never to stop their medication abruptly and to maintain steady hydration, especially in hot Nigerian climates where fluid loss can rapidly elevate lithium levels. Women should also be instructed to report any planned or confirmed pregnancies immediately so clinicians can review their medication regimen. Providing non-judgmental, compassionate education empowers mothers to participate actively in their psychiatric care while safeguarding their own health and their baby's development.